Why is Zydus Wellness falling/rising?

Recent Price Movement and Market Context

Zydus Wellness has experienced a notable decline over the past week, with the stock dropping 5.57% while the Sensex remained virtually flat, registering a marginal 0.01% gain. This underperformance has extended over the last month, where the stock fell 12.12% against the Sensex’s 2.70% rise. Year-to-date, the stock has managed a modest 4.81% gain, yet this lags behind the broader market’s 9.69% increase. Over longer horizons, the stock’s returns continue to trail key indices, with a 1-year return of -1.07% compared to Sensex’s 4.83%, and a 3-year return of 25.82% versus 36.41% for the benchmark.

On 05-Dec, the stock touched an intraday low of ₹406.25, marking a 2.38% decline for the day. Notably, the stock has been on a consecutive nine-day losing streak, cumulatively falling 8.9% during this period. This sustained weakness is compounded by falling investor participation, with delivery volumes on 04-Dec dropping 13.15% below the five-day average, signalling reduced buying interest. Although the stock remains above its 200-day moving average, it is trading below its 5-day, 20-day, 50-day, and 100-day averages, indicating short- to medium-term bearish momentum.

Fundamental Challenges Impacting the Stock

Despite a strong ability to service debt, evidenced by an average EBIT to interest coverage ratio of 14.57, Zydus Wellness faces significant headwinds in profitability and growth. The company’s return on capital employed (ROCE) stands at a modest 3.8%, with an enterprise value to capital employed ratio of 1.8, suggesting a fair but premium valuation relative to peers. However, the stock’s premium pricing has not translated into robust returns, as profits have declined by 8.4% over the past year.

Institutional investors hold a substantial 22.19% stake in the company, reflecting confidence from sophisticated market participants who typically conduct thorough fundamental analysis. Yet, this has not prevented the stock from underperforming, highlighting concerns about the company’s operational performance and growth prospects.

Weak Earnings and Growth Metrics

One of the primary reasons for the stock’s decline is the company’s poor earnings trajectory. The latest quarterly results reveal a sharp deterioration, with profit before tax excluding other income (PBT less OI) plunging to a loss of ₹17.80 crores, a decline of 121.3% compared to the previous four-quarter average. Similarly, the net profit after tax (PAT) fell by 123.1% to a loss of ₹18.60 crores, while earnings per share (EPS) hit a low of ₹-1.66.

Long-term growth has also been underwhelming. Over the past five years, net sales have grown at an annualised rate of 11.17%, while operating profit has expanded by only 4.33% annually. This sluggish growth, combined with deteriorating profitability, has contributed to the stock’s underperformance relative to the BSE500 index over one year, three years, and the recent three-month period.

Investor Sentiment and Outlook

The combination of declining profits, weak earnings per share, and underwhelming growth has weighed heavily on investor sentiment. The stock’s recent nine-day losing streak and falling volumes suggest that market participants are increasingly cautious. While the company’s strong debt servicing capability and fair valuation metrics provide some support, these positives are overshadowed by the fundamental challenges that have led to sustained underperformance against benchmarks.

In summary, Zydus Wellness’s share price decline on 05-Dec and over recent weeks is primarily driven by disappointing quarterly earnings, subdued long-term growth, and a valuation premium that has not been justified by financial performance. Investors appear to be reacting to these factors by reducing exposure, resulting in the stock’s continued downward trajectory.

Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →